ID 109939
タイトルヨミ
クリゾチニブ ガ ソウコウ シタ Performance Status フリョウ anaplastic lymphoma kinase イデンシ テンザ ヨウセイ ハイセンガン ノ 1レイ
タイトル別表記
A case of anaplastic lymphoma kinase-positive non-small cell lung cancer with a poor performance status successfully treated with crizotinib
著者
梶田, 敬介 徳島大学病院卒後臨床研修センター
坂口, 暁 徳島大学病院呼吸器・膠原病内科
手塚, 敏史 徳島大学病院呼吸器・膠原病内科 KAKEN研究者をさがす
埴淵, 昌毅 徳島大学病院呼吸器・膠原病内科 KAKEN研究者をさがす
キーワード
crizotinib
anaplastic lymphoma kinase
non-small cell lung cancer
performance status
資料タイプ
学術雑誌論文
抄録
A 27-year-old female was referred to our hospital for further examination of hoarseness, cough, and hemoptysis. Positron emission tomography-computed tomography revealed FDG accumulation in a huge mass in the left lower lobe, lymph nodes in the hilum, mediastinum and right cervical lesion left scapula and vertebral body. Further examination yielded the diagnosis of primary lung adenocarcinoma (cT2aN3M1b : Stage IV) harboring the anaplastic lymphoma kinase (ALK) fusion oncogene. Although her general condition was getting worse due to rapid increase of the pleural effusion, crizotinib promptly diminish the pleural effusion and ameliorated the patient’s condition. The adverse events of crizotinib, such as nausea, vomiting and visual disturbance, were generally mild and well tolerable during treatment. These findings suggest that crizotinib is a promising candidate for ALK-positive non-small cell lung cancer patients even with poor performances.
掲載誌名
四国医学雑誌
ISSN
00373699
cat書誌ID
AN00102041
出版者
徳島医学会
71
5-6
開始ページ
141
終了ページ
148
並び順
141
発行日
2015-12-25
EDB ID
フルテキストファイル
言語
jpn
著者版フラグ
出版社版
部局
病院
医学系